Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Experience matters with DES: The volume of drug-eluting coronary stent implants performed at a center is inversely related to the rates of myocardial infarction and death for the patients, according to data from the German Cypher Registry to be published in the Aug. 18 issue of Circulation. The analysis includes outcomes from 8,201 patients implanted with Johnson & Johnson/Cordis' Cypher sirolimus-eluting stents at 51 centers in Germany between April 2002 and September 2005. Centers that recruited over 400 sirolimus-eluting stent patients during the study period reported an all-cause mortality rate of 0.3% and a myocardial infarction rate of 0.5%. The death and MI rates for centers with between 150 and 400 Cypher patients were 0.6% and 1.2%, and the death and MI rates for centers with fewer than 150 Cypher patients were 0.7% and 1.7%
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.